181 related articles for article (PubMed ID: 19302955)
1. Expression of epithelial cell adhesion molecule and pituitary tumor transforming gene in adamantinomatous craniopharyngioma and its correlation with recurrence of the tumor.
Tena-Suck ML; Ortiz-Plata A; Galán F; Sánchez A
Ann Diagn Pathol; 2009 Apr; 13(2):82-8. PubMed ID: 19302955
[TBL] [Abstract][Full Text] [Related]
2. Possible linkage between specific histological structures and aberrant reactivation of the Wnt pathway in adamantinomatous craniopharyngioma.
Kato K; Nakatani Y; Kanno H; Inayama Y; Ijiri R; Nagahara N; Miyake T; Tanaka M; Ito Y; Aida N; Tachibana K; Sekido K; Tanaka Y
J Pathol; 2004 Jul; 203(3):814-21. PubMed ID: 15221941
[TBL] [Abstract][Full Text] [Related]
3. Osteonectin expression in surrounding stroma of craniopharyngiomas: association with recurrence rate and brain infiltration.
Ebrahimi A; Honegger J; Schluesener H; Schittenhelm J
Int J Surg Pathol; 2013 Dec; 21(6):591-8. PubMed ID: 23648679
[TBL] [Abstract][Full Text] [Related]
4. Epithelial cell adhesion molecule (EpCAM) expression in adamantinomatous craniopharyngioma.
Gires O
Ann Diagn Pathol; 2009 Dec; 13(6):428-9. PubMed ID: 19917481
[No Abstract] [Full Text] [Related]
5. Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma.
Coy S; Rashid R; Lin JR; Du Z; Donson AM; Hankinson TC; Foreman NK; Manley PE; Kieran MW; Reardon DA; Sorger PK; Santagata S
Neuro Oncol; 2018 Jul; 20(8):1101-1112. PubMed ID: 29509940
[TBL] [Abstract][Full Text] [Related]
6. Clinico-pathological and immunohistochemical characteristics associated to recurrence/regrowth of craniopharyngiomas.
Tena-Suck ML; Salinas-Lara C; Arce-Arellano RI; Rembao-Bojórquez D; Morales-Espinosa D; Sotelo J; Arrieta O
Clin Neurol Neurosurg; 2006 Oct; 108(7):661-9. PubMed ID: 16500745
[TBL] [Abstract][Full Text] [Related]
7. Expression of aberrant beta-catenin and impaired p63 in craniopharyngiomas.
Cao J; Lin JP; Yang LX; Chen K; Huang ZS
Br J Neurosurg; 2010 Jun; 24(3):249-56. PubMed ID: 20128632
[TBL] [Abstract][Full Text] [Related]
8. Differential Expression of Stem Cell Markers in Human Adamantinomatous Craniopharyngioma and Pituitary Adenoma.
Chang CV; Araujo RV; Cirqueira CS; Cani CM; Matushita H; Cescato VA; Fragoso MC; Bronstein MD; Zerbini MC; Mendonca BB; Carvalho LR
Neuroendocrinology; 2017; 104(2):183-193. PubMed ID: 27161333
[TBL] [Abstract][Full Text] [Related]
9. Pituitary tumor transforming gene and insulin-like growth factor 1 receptor expression and immunohistochemical measurement of Ki-67 as potential prognostic markers of pituitary tumors aggressiveness.
Sánchez-Tejada L; Sánchez-Ortiga R; Moreno-Pérez O; Montañana CF; Niveiro M; Tritos NA; Alfonso AM
Endocrinol Nutr; 2013; 60(7):358-67. PubMed ID: 23416216
[TBL] [Abstract][Full Text] [Related]
10. Does the calcification of adamantinomatous craniopharyngioma resemble the calcium deposition of osteogenesis/odontogenesis?
Song-Tao Q; Xiao-Rong Y; Jun P; Yong-Jian D; Jin L; Guang-Long H; Yun-Tao L; Jian R; Xiang-Zhao L; Jia-Ming X
Histopathology; 2014 Feb; 64(3):336-47. PubMed ID: 24387671
[TBL] [Abstract][Full Text] [Related]
11. Pituitary tumor-transforming gene expression is a prognostic marker for tumor recurrence in squamous cell carcinoma of the head and neck.
Solbach C; Roller M; Eckerdt F; Peters S; Knecht R
BMC Cancer; 2006 Oct; 6():242. PubMed ID: 17029632
[TBL] [Abstract][Full Text] [Related]
12. Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study.
Filippella M; Galland F; Kujas M; Young J; Faggiano A; Lombardi G; Colao A; Meduri G; Chanson P
Clin Endocrinol (Oxf); 2006 Oct; 65(4):536-43. PubMed ID: 16984249
[TBL] [Abstract][Full Text] [Related]
13. Epithelial cell adhesion molecule expression in pituitary adenomas: an immunohistochemical study.
Ortiz-Plata A; Moreno-Leyva K; López-Gómez M; Santos-Salinas S; Sánchez-García A; Tena-Suck ML
Ann Diagn Pathol; 2010 Dec; 14(6):418-24. PubMed ID: 21074690
[TBL] [Abstract][Full Text] [Related]
14. Impact of the Canonical Wnt Pathway Activation on the Pathogenesis and Prognosis of Adamantinomatous Craniopharyngiomas.
Jucá CEB; Colli LM; Martins CS; Campanini ML; Paixão B; Jucá RV; Saggioro FP; de Oliveira RS; Moreira AC; Machado HR; Neder L; Antonini SR; de Castro M
Horm Metab Res; 2018 Jul; 50(7):575-581. PubMed ID: 29625497
[No Abstract] [Full Text] [Related]
15. Immunohistochemical study of craniopharyngiomas.
Kubo O; Tajika Y; Uchimuno H; Muragaki Y; Shimoda M; Hiyama H; Morishita K; Takakura K
Noshuyo Byori; 1993; 10(2):131-4. PubMed ID: 7693229
[TBL] [Abstract][Full Text] [Related]
16. Periostin activates pathways involved in epithelial-mesenchymal transition in adamantinomatous craniopharyngioma.
Chen M; Zheng SH; Liu Y; Shi J; Qi ST
J Neurol Sci; 2016 Jan; 360():49-54. PubMed ID: 26723972
[TBL] [Abstract][Full Text] [Related]
17. Clinical and prognostic role of annexin A2 in adamantinomatous craniopharyngioma.
Wang Y; Deng J; Guo G; Tong A; Peng X; Chen H; Xu J; Liu Y; You C; Zhou L
J Neurooncol; 2017 Jan; 131(1):21-29. PubMed ID: 27640198
[TBL] [Abstract][Full Text] [Related]
18. MIB-1 immunoreactivity in craniopharyngiomas: a clinico-pathological analysis.
Duò D; Gasverde S; Benech F; Zenga F; Giordana MT
Clin Neuropathol; 2003; 22(5):229-34. PubMed ID: 14531547
[TBL] [Abstract][Full Text] [Related]
19. Interleukin‑6 induces an epithelial‑mesenchymal transition phenotype in human adamantinomatous craniopharyngioma cells and promotes tumor cell migration.
Zhou J; Zhang C; Pan J; Chen L; Qi ST
Mol Med Rep; 2017 Jun; 15(6):4123-4131. PubMed ID: 28487953
[TBL] [Abstract][Full Text] [Related]
20. Expression of human MCM6 and DNA Topo II alpha in craniopharyngiomas and its correlation with recurrence of the tumor.
Xu J; Zhang S; You C; Huang S; Cai B; Wang X
J Neurooncol; 2007 Jun; 83(2):183-9. PubMed ID: 17410335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
